

Thyas Co. Ltd.

http://thyas.co.jp/

Email hitoshi@thyas.co.jp

Products

Immunotherapy leveraging the potential of T cells is attracting significant attention as a promising treatment. At Thyas, we are aiming towards the development of a treatment for chronic infectious diseases and cancers, using auto-transplantation. The process involves choosing T cells that recognize infectious cells or cancer cells from the patent, transform it into iPS cells and then manufacture the T cells. These cells are then used in the auto-transplantation. This technique is based on the technique developed by Shin Kaneko, the Associate Professor of Kyoto University's Center for iPS Cell Research and Application (CiRA). T cells produced using this method has a high level of idiosyncrasy and proliferating ability, and possess strong cytotoxicity. Another advantage is the ability to produce a large and stable amount of cells. We are in the stage of optimizing the cell-manufacturing method and developing a product testing method. Our next steps are to perform clinical trials using the T cells formulation, demonstrate safety and effectiveness, obtain approval, and finally deliver the T cell formulation to many patients.

Message

At Thyas Co. Ltd., all employees are in unison to devote to the research and development in order to provide a new treatment to many patients using T cells derived from iPS cells. We sincerely hope that we could receive all the more support and encouragement. Please do not hesitate to contact us if you are interested in our technology and our T cell treatment.

Reference information

[Invention]

- Induction method from pluripotent stem cells to T cells (PCT/JP2015/081959)
- CD4CD8 manufacturing method of double-positive T cells (PCT/JP2017/022840) [Joint-research]

The National University Corporation Kyoto University, Kawasaki Gakuen Corporation's Kawasaki Medical School, and the National Research and Development Agency the National Cancer Center.

